AstraZeneca's SEC Form 6-K reveals promising results for Datroway in metastatic triple-negative breast cancer, showing significant survival improvements in patients not eligible for immunotherapy.
Explore Astronics Corporation's 8-K filing, reporting significant events as of February 21, 2025. Stay informed on stock performance and industry insights.
Discover Alterity Therapeutics Limited's latest SEC Form 6-K, detailing A$40M raised for ATH434's development targeting Multiple System Atrophy (MSA).
Explore Astronics Corporation's 8-K filing details from January 10, 2025. Key insights on stock, exchange, and significant corporate updates.
Explore the significant developments from Sigmatron International, Inc.'s 8-K filing on December 20, 2024. Discover insights on stock performance, compliance, and recent corporate actions.